Shanghai Fosun Pharmaceutical Group Co Ltd (600196) — Cash Flow Reinvestment Rate
Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has a Cash Flow Reinvestment Rate of 0.85x as of December 2025, reinvesting CN¥2.03 Billion (capex CN¥1.28 Billion plus investments CN¥753.03 Million) from operating cash flow of CN¥2.40 Billion. See 600196 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Shanghai Fosun Pharmaceutical Group Co Ltd Cash Flow Reinvestment Rate (1998–2025)
Historical reinvestment intensity for Shanghai Fosun Pharmaceutical Group Co Ltd across 28 annual periods. For the full cash flow conversion analysis, see how efficiently does Shanghai Fosun Pharmaceutical Group Co L generate cash.
Annual Cash Flow Reinvestment Rate for Shanghai Fosun Pharmaceutical Group Co Ltd (1998–2025)
Year-by-year capital reinvestment analysis for Shanghai Fosun Pharmaceutical Group Co Ltd. See Shanghai Fosun Pharmaceutical Group Co L leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.12x | CN¥6.75 Billion | CN¥6.01 Billion | CN¥4.45 Billion | ▼ -0.5% |
| 2024 | 1.13x | CN¥5.06 Billion | CN¥4.48 Billion | CN¥4.41 Billion | ▼ -46.1% |
| 2023 | 2.10x | CN¥9.16 Billion | CN¥4.36 Billion | CN¥5.34 Billion | ▼ -0.7% |
| 2022 | 2.11x | CN¥8.91 Billion | CN¥4.22 Billion | CN¥5.89 Billion | ▲ +60.9% |
| 2021 | 1.31x | CN¥5.19 Billion | CN¥3.95 Billion | CN¥4.97 Billion | ▼ -34.1% |
| 2020 | 1.99x | CN¥5.14 Billion | CN¥2.58 Billion | CN¥4.44 Billion | ▼ -20.8% |
| 2019 | 2.52x | CN¥8.11 Billion | CN¥3.22 Billion | CN¥3.96 Billion | ▲ +42.6% |
| 2018 | 1.76x | CN¥5.21 Billion | CN¥2.95 Billion | CN¥3.17 Billion | ▲ +34.4% |
| 2017 | 1.31x | CN¥3.39 Billion | CN¥2.58 Billion | CN¥2.17 Billion | ▼ -36.6% |
| 2016 | 2.07x | CN¥4.37 Billion | CN¥2.11 Billion | CN¥1.92 Billion | ▲ +41.5% |
| 2015 | 1.46x | CN¥2.37 Billion | CN¥1.62 Billion | CN¥1.24 Billion | ▲ +56.9% |
| 2014 | 0.93x | CN¥1.12 Billion | CN¥1.20 Billion | CN¥1.12 Billion | ▼ -9.3% |
| 2013 | 1.03x | CN¥1.04 Billion | CN¥1.01 Billion | CN¥1.04 Billion | ▼ -41.0% |
| 2012 | 1.74x | CN¥1.16 Billion | CN¥665.52 Million | CN¥1.16 Billion | ▼ -30.7% |
| 2011 | 2.52x | CN¥796.83 Million | CN¥316.65 Million | CN¥796.83 Million | ▲ +50.9% |
| 2010 | 1.67x | CN¥339.17 Million | CN¥203.36 Million | CN¥339.17 Million | ▲ +25.5% |
| 2009 | 1.33x | CN¥348.07 Million | CN¥261.87 Million | CN¥348.07 Million | ▲ +47.1% |
| 2008 | 0.90x | CN¥210.63 Million | CN¥233.04 Million | CN¥210.63 Million | ▼ -43.3% |
| 2007 | 1.59x | CN¥209.71 Million | CN¥131.48 Million | CN¥209.71 Million | ▲ +10.6% |
| 2006 | 1.44x | CN¥266.61 Million | CN¥184.91 Million | CN¥266.61 Million | ▲ +22.0% |
| 2005 | 1.18x | CN¥222.60 Million | CN¥188.35 Million | CN¥222.60 Million | ▲ +18.2% |
| 2004 | 1.00x | CN¥205.02 Million | CN¥205.10 Million | CN¥205.02 Million | ▼ -43.2% |
| 2003 | 1.76x | CN¥264.05 Million | CN¥150.14 Million | CN¥264.05 Million | ▲ +29.2% |
| 2002 | 1.36x | CN¥139.52 Million | CN¥102.47 Million | CN¥139.52 Million | ▼ -34.4% |
| 2001 | 2.08x | CN¥141.51 Million | CN¥68.15 Million | CN¥141.51 Million | ▲ +127.0% |
| 2000 | 0.91x | CN¥126.63 Million | CN¥138.43 Million | CN¥126.63 Million | ▼ -55.2% |
| 1999 | 2.04x | CN¥77.99 Million | CN¥38.20 Million | CN¥77.99 Million | ▲ +160.1% |
| 1998 | 0.79x | CN¥52.25 Million | CN¥66.55 Million | CN¥52.25 Million | — |